A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Inclusion Criteria: * Written informed consent obtained prior to any study-specific procedures not considered part of routine medical care * Histologically or cytologically confirmed unresectable or medically inoperable malignant pleural mesothelioma * Disease progression after treatment with at least one line of chemotherapy that included a first-line platinum agent in combination with an anti-folate * Participants must have measurable disease according to modified RECIST for pleural malignant mesothelioma. (Bone metastases are not considered measurable.) Prior radiation to the only site of measurable disease will make the participant ineligible unless the lesion has been demonstrated to grow after completion of radiation therapy. * Participants must be willing and able to undergo a biopsy at the start of this study and an on-treatment biopsy if safe and feasible. * Participants must have be at least 28 days from any major surgery. * ECOG performance status of 0 or 1. * Subjects must have adequate hematologic, renal, and organ and marrow function * Age 18 years or older * Female subjects of childbearing potential who are sexually active with a non sterilized male partner must agree to use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of investigational product. Male partners of a female subject must also agree to use male condom plus spermicide throughout th…